Post on 26-Jul-2020
transcript
4/5/2018
1
Give us this day our daily bread….
1
Bagels, Biscuits, Baguettes, and Schizophrenia
April 4, 2018p
William W. Eaton
4/5/2018
2
Outline
• The puzzle of Schizophrenia
• Wheat and Schizophrenia• Wheat and Schizophrenia
• Leaky gut and Gluten Sensitivity
• Results from R34
• Design of Double Blind RCT
S h f M h i• Search for Mechanisms
3
The Puzzle of Schizophrenia
4/5/2018
3
Skepticism about sociocultural factors
Writing … a review of studies of the social etiology of schizophrenia is like talking with the relatives of the
Outlook from 30-50 years ago
sc op e a s e ta g t t e e at es o t edeceased after returning from the funeral. Other than some platitudes, there is little that can be suggested that would remedy, alleviate, or eliminate the trouble. Mishler and Scotch, Psychiatry, 1963
Skepticism about genetics
5 © 2009, Johns Hopkins University. All rights reserved.
In short, the extent of the genetic component, if any, in DSM-III schizophrenia remains unresolved. Pope et al, American Journal of Psychiatry, June 1982.
Descriptive versus mechanistic diagnosis
Jerry Morris’ 7th use of epidemiology
6 From Leboyer et al, BMC Medicine, 2016
4/5/2018
4
Odds Ratios and 95% Confidence Intervals in 8 studies Author Date Sample
Ross et al. 1950 1608
Arthritis and Schizophrenia
Pilkington 1955 318
Baldwin 1980 7718
Mohamed et al. 1982 162
Allebeck et al. 1985 11342
Oken & Schulzer 1999 229972
7
Oken & Schulzer 1999 1984
Mors et al. 1999 20495
.05 0.1 0.2 0.5 1.0
2.0 5.0
Source: Eaton and Chen, 2004
Schizophrenia: Autoimmune Disease?
• Clinical findings that suggest Schizophrenia might be some sort of autoimmune disease
– Relapsing course with unpredictable episodes
– Autoantibodies can produce psychosis (SLE)
– Immunologic abnormalities (Ganguli et al, 1987, 1993)
Decreased IL 2
8
• Decreased IL 2
• Increased IL 2 receptors
• Increased IL 6
4/5/2018
5
1985
9
Wheat and Schizophrenia
4/5/2018
6
Source: Main Line Times, Thursday, November 14, 1991
1986
“It was fun.”
4/5/2018
7
13
• Gluten is a protein composite found in foods containing wheat
What is Gluten?
found in foods containing wheat, barley and rye
• Gives elasticity to dough, helping it to rise and keep its shape
• The composite is gliadin and glutenin (gliadin is alcohol soluble g (gand glutenin is insoluble in dilute acids).
• Gluten is fairly indigestible in most people
4/5/2018
8
CHFIQPQQPFPQQPQQSFPQQQPSLIKEnter this sequence of amino acids:
NCBI: National Center for Biotechnology Information
15
During World War II, as wheat consumption went
Wheat and Schizophrenia
wheat consumption went down in Scandinavia, admissions for schizophrenia went down; as wheat consumption in the United States went up, admissions for schizophrenia went up.
Dohan, Acta, 1966
4/5/2018
9
Schizophrenia is almost non-existent
Wheat and schizophrenia
existent in populations consuming little or no grain
Source: Dohan, Harper, et al. Is schizophrenia rare if grain is rare? Biological Psychiatry 1984; 19: 385-399.
1973
18
4/5/2018
10
19
14 persons with schizophre
i ith 6nia with 6 weeks of gluten withdrawal, followed by four weeks of addition
20
of gluten(Singh and Kay, 1976)
Singh and Kay, 1976
4/5/2018
11
Author Date Sample Results
Dohan 1969 102 62% discharged versus 32%
Dohan/Grasberger 1973 115 37% to open ward versus 16%
Clinical Trials of Withdrawal of Gluten Withdrawal in Schizophrenia
Singh and Kay 1976 14 Improvement on 30/39 measures
Rice 1978 16 Two improved
Potkin 1981 8 No change in functioning
Storms 1982 26 No change in functioning
21
Osborne 1982 4 No change in functioning
Vlissides 1986 24 Improvement in 5/12 measures
Kelly/Eaton 2016 16 Improvement in SANS
Case study of Schizophrenia, celiac disease, and hypofrontality
Before gluten-free diet hypofrontality is present
Hypofrontality not present six months after start of gluten-free diet
22
Source: De Santis et al. Schizophrenic symptoms and SPECT abnormalities in a coeliac patient: regression after a gluten-free diet. Journal of Internal Medicine 1997; 242:421-423.
start of gluten free diet
4/5/2018
12
23
William W. Eaton, Lian-yu Chen, Curtis Dohan, Jr., Deanna Kelly, Nicola Cascella
Prior Celiac Disease raises risk for Schizophrenia
Data from linked Danish National Case Registers Prevalence/1,000 Relative Risk*
Cases Controls Univariate Adjusted Celiac 1.5 0.5 3.2 3.2 (1.8–5.9) Chron’s Disease 4.5 3.4 1.3 1.4 (1.0–1.9) Ulcerative Colitis 6.2 4.7 1.3 1.4 (1.0–1.8)
24Continued
Source: Eaton et al, BMJ, 2004
4/5/2018
13
Autoimmune Diseases and risk for Schizophrenia in Denmark
25Source: Eaton et al, AJP, 2006
Autoimmune Diseases and risk for Schizophrenia in Denmark
45% increased i k frisk for
schizophreniafor persons with history of any autoimmune disease
26Source: Eaton et al, AJP, 2006
disease
4/5/2018
14
• “… anti-endomysial and antigliadin antibodies are noninvasive and nonexpensive tests and should be
Screening for Celiac Disease?
pperformed to screen patients with schizophrenic symptoms, in order to exclude coeliac disease as a potentially treatable condition.”
• De Santis et al, JIG, 1997)
27
Leaky gut, Celiac Disease, and Gluten Sensitivity
4/5/2018
15
Lancet, 2000
29
ANYAS, 2012
30
4/5/2018
16
Non-celiac gluten sensitivity (NCGS) now y ( )recognized as one of many gluten-related diseases. Presumed to involve innate immunity, not adaptive immunity .
31
32
4/5/2018
17
33
Tight junctions are important for immune function.PNAS, 2009
34
Prehaptoglobin 2 is now recognized as a candidate gene for schizophreniaWell waddya know?
4/5/2018
18
Schizophrenia and Gliadin: Defining a Subgroup
• Gliadin is a protein found in wheat, barley and rye which may trigger different types of immune reactionsy gg yp
• An immune reaction to gliadin can occur in 3 forms: Celiac Disease, Non-Celiac Gluten Sensitivity (Gluten Sensitivity) and wheat allergy
• Gluten Sensitivity is a different type of immune response than Celiac Disease
• No prior work has examined effects of gluten-free diet in a subgroup having gluten sensitivity
R34 Developmental Study
4/5/2018
19
Author Year N patients % positive N healthy % positive Odds ratio
Anti‐gliadin IgA
Reichelt 1995 48 19% 13 0 6.3
Dickerson 2010 NA NA NA NA 2.0/2.7
Cascella 2011 1401 23% 900 3 1 9 3
IgA and IgG Antigliadin Antibodies in schizophrenia and controls
Cascella 2011 1401 23% 900 3.1 9.3
Sidhom 2012 47 4.5% 41 10.5% 0.4
Jin 2012 473 27% 41 10.5% 1.7
Pooled IgA OR 2.57
Anti‐gliadin IgG
Dickerson 2010 NA NA NA NA 5.5/6.2
37
Cascella 2011 1401 1.4% 900 3.3% 0.4
Sidhom 2012 47 59% 41 23.9% 4.6
Jin 2012 419 17.9% 478 14.2% 1.3
Okusaga 2013 950 21.9% 1000 10.0 2.13
Lachance and McKenzie, Schizophrenia Research 2013 Pooled IgG OR 2.31
IgG AGA levels in 160 persons with schizophrenia and 80 healthy controlsSamples from Baltimore
AGA IgGAGA IgGmore important than AGA IgA
38
4/5/2018
20
Randomized Double‐Blind Feasibility Study of a Gluten‐Free Diet in People with Schizophrenia and Elevated AntigliadinAntibodies (AGA IgG)Poster to be presented at the Schizophrenia International Research Society Congress
lApril 4‐8, 2018
Deanna L. Kelly1, Haley Demyanovich1, Katrina Rodriguez2, Daniela Cihakova2, Monica V. Talor2, James Gold1, Sharon August1, Robert W. Buchanan1, Stephanie M. Feldman1, Fang Liu1, William T. Carpenter, Jr.1, William W. Eaton2
39
1Maryland Psychiatric Research Center, University of Maryland School of Medicine; 2Johns Hopkins University
Randomized Double-Blind Gluten-Free Diet Study
• Double-blind randomized gluten-free inpatient feasibility study for 5 weeks
• All participants received a gluten free diet – Protein shake daily with 10 gm of Gluten flour or 10 gm of Rice flour
• Participants discharged on gluten free diet evaluated for 8Participants discharged on gluten free diet, evaluated for 8 weeks
• First study in schizophrenia to select subjects based on antibodies, but not powered to find an effect
• Clinical Trials.gov NCT#01927276 (NIMH funded R34)
Kelly D, Eaton WW, et al. In preparation, 2018
Slide from D. Kelly, CPNP
4/5/2018
21
Inclusion/Exclusion CriteriaInclusion• DSM-IV/DSM 5 diagnosis of
schizophrenia or schizoaffective
Exclusion• Already on gluten free diets
P iti it t tip
disorder • Positive for gliadin antibodies
(IgG ≥ 20 U)• Age 18- 64 years• BPRS total score >29• Same antipsychotic for at least
4 weeks
• Positivity to tissue transglutaminase (tTg) antibodies or known history of Celiac Disease
• Pregnant or lactating females
• Meets DSM-5 criteria for alcohol or substance use disorder (other than nicotine) within last month4 weeks
• Ability to consent determined by a score of ≥ 10 on the Evaluation to Sign Consent
than nicotine) within last month
• Gluten ataxia (Brief Ataxia Rating Scale)
Slide from D. Kelly, CPNP
375 screened for Antigliadin Antibodies
26 completed eligibility
100/370 positive for AGA (27%)64 recruited for inpatient study
5 excluded for tTG positivity
PARTICIPANT FLOW
DIAGRAM GLUTEN‐FREE DIET STUDY 26 completed eligibility
screening for inpatient study
19 randomized
Gluten Free Diet (N=7)
Gluten Containing Diet (N=9)
2 excluded <20 U AGA IgG
1 excluded: <20 U AGA IgG
2 Withdrawals:1 Beginning of week 4: Personal choice1 End of Week 4: Housing Reasons
N=7 completed
N=7 completed
8 Post Discharge Randomized Open-Label Follow-Up of
Gluten Free Diet
N=5 assessed at 8 weeks
N=3 assessed at 8 weeks
Slide from D. Kelly, CPNP
4/5/2018
22
Demographic and Clinical InformationGluten‐Containing
Diet (N=9)
Gluten‐Free Diet (N=7) Statistics
Mean age (Years) 42.0 ± 14.6 32.5 ± 9.7 p=0.22
Sex (Male) N=5 (56%) N=4 (57%) p=1.00
Race (African American) N=7 (78%) N=5 (71%) p=1.00
Age of Illness onset (Years) 16.9 ± 3.4 18.2 ± 2.4 p=0.61
Level of Education (Years) 11.8 ± 1.3 12.4 ± 2.1 p=0.29
Smokers N=5 (56%) N=6 (86%) p=0.20
Body Mass Index (kg/m2) 28.5 ± 4.7 31.4 ± 8.9 p=0.71
Baseline AGA IgG (U) 55.8 ± 28.6 43.8 ± 12.2 p=0.56
Baseline AGA IgA (U) 23.6 ± 21.1 32.9 ± 28.3 p=0.49
Antipsychotics
First‐Generation Antipsychotics (FGA)
Second‐Generation Antipsychotics (SGA)
Clozapine
N=2 (22%)
N=2 (22%)
N=2 (22%)
N=2 (29%)
N=2(29%)
N=1 (14%)
p=0.96
Clozapine
SGA + FGA
N 2 (22%)
N=3 (33%)
N 1 (14%)
N=2 (29%)
Antidepressants
Anticholinergic medications
N=6 (67%)
N=7 (78%)
N=3 (43%)
N=6 (86%)
p=0.34
p=0.69
Meals per day with gluten 1.7 ± 1.1 2.1 ± 1.2 p=0.52
Gastrointestinal Disorder
Dermatologic Disorder
N=4 (44%)
N=1 (11%)
N=4 (57%)
N=3 (43%)
p=0.53
P=0.13
Kelly D, Eaton WW, et al. In preparation, 2018 Slide from D. Kelly, CPNP
ES=‐0 34
AGA IgG
50
6016% Decrease
34% Decrease
0.34
34% Decrease
16% Decrease20
30
40
50
Kelly D, Eaton WW, et al. In preparation, Slide from D. Kelly, CPNP88
0
10
Gluten‐Containing Diet (N=9) Gluten‐Free Diet (N=7)
Baseline Endpoint
4/5/2018
23
Mean AGA IgG by Haptoglobin Gene Polymorphism
30
35
Mean AGA IgG (U) in schizophrenia group
N=47
N=30
10
15
20
25
30
N=23
> 20 U considered elevated
0
5
Genotype 1‐1 Genotype 1‐2 Genotype 2‐2
Baseline
Gluten‐
Containing
Diet (N=9)
Endpoint
Gluten‐
Containing
Diet (N=9)
Baseline
Gluten‐Free
Diet
(N=7)
Endpoint
Gluten‐Free
Diet
(N=7)
Treatment Effects
Total BPRS 37.4 ± 6.2 31.1 ± 5.5 35.9 ± 5.4 31.6 ± 6.7 ES= 0.40 F=0.05,
df=10.7, p=0.83
Positive
symptoms
7.3 ± 1.9 7.0 ± 2.3 5.9 ± 1.1 6.4 ± 1.6 ES= 0.39 F=0.22,
df=14.1, p=0.64
Calgary
Depression
Rating Scale
4.8 ± 3.2 1.9 ± 1.6 2.4 ± 2.5 1.6 ± 1.3 ES= 0.13 F=0.00,
df=1,13.7, p=0.95
CGI 3.9 ± 0.6 3.9 ± 0.4 4.1 ± 0.7 3.6 ± 0.8 ES= ‐0.75 F=2.36,
df=1,13.1, p=0.15
F=4.76, df=53.2, p=0.0023
46
Tx x Time
4/5/2018
24
No change in Simpson Angus0.4
0.5
0.6
0.7
0.8 MATRICS Consensus Cognitive BatteryEffect Sizes
No change in Simpson Angus Scale F=0.3, df=1,14, p=0.59;
Barnes Akathisia Scale F=2.92, 1,14, p=1.09, or in BMI F=0.10, 1,12.6, p=0.76
‐0.3
‐0.2
‐0.1
0
0.1
0.2
0.3
47
0.3
Change in SANS Score in double blind RCTPersons with schizophrenia and IgG AGA
7 gluten free and 9 gluten containing diet
First difference week 2 (t=2.37, df=1,12.7, p=0.03); The total score is driven by robust effects in avolition (d=0.5), blunted affect (d=1.1), and alogia (d=0.7). Eaton, Kelly, unpublished data
4/5/2018
25
Correlation of AGA IgG and TNF-ᾳIn 100 persons with schizophrenia
Proinflammatory Cytokines and AGA IgG
In 100 persons with schizophreniaR=0.42
Correlation of AGA IgG and IL-1β
49
In 100 persons with schizophreniaR=0.51
Kelly et al, Brain, Behavior and Immunity, 2018
Initial Zonulin Work• Mean zonulin levels in
schizophrenia were 2.38 mg/dL(SD 1.23 mg/dL)
• Zonulin or cytokines do notp = .024*
2.5
Effect of IL-1β vs. zonulin-IL-1β Interaction on BPRS
score Zonulin or cytokines do not relate to psychiatric symptoms
• Zonulin with cytokines leads to prediction of total BPRS
• For example, zonulininteracts with IL-1β on:
– BPRS total (p=.024),
p = .014*p = .000*
p = .709p = .113
p = .027*
0
0.5
1
1.5
2
Sta
nd
ard
co
effic
ien
ts (
bet
a) IL-1β
Zon*IL-1β
(p ),
– BPRS hostility (p<.0001)
– BPRS anxiety/depression (p=.027)
Kelly D, et al. Presented at the American College of Neuropsychopharmacology (ACNP), December 2017
p = .282 p = .131 p = .642p = .131 p = .490p = .430
-0.5
0
4/5/2018
26
Design of Double Blind Randomized Controlled Trial
2017
52
Full-scale trial, Funded
4/5/2018
27
Identify persons with schizophrenia who are 18-45 from EPIC
Send Recruitment Letter to home address
Meet before or after next therapy sessionE l i h
Screening Procedures
Explain researchEvaluate Ability to sign ConsentObtain consentDraw blood
Assay for IgG AGA and IgG tTG
53
Positive for IgG tTG (celiac disease)refer to therapist and recommend contact with physician
Positive for IgG AGAsend information to Maryland Psychiatric Research Center
Negative for IgG AGA and IgG tTGsend letter stating negative results
MPRC Contact Potential Recruit JHU 500 300
350 - 150+ AGA IgG Assay 90+ 210 -
240
Screening 800 to recruit 60 for inpatient trial
240
140 Recruit for visit 100 decline to visit
120 SCID positive 20 SCID negative
40 Exclusion + 80 Inclusion +
54
40 Exclusion + 80 Inclusion +
20 decline 60 Enter trial
30 Treatment 30 Control
4/5/2018
28
Confirmation of diagnosis with SCIDScreening for exclusion criteria60 persons starting, ~50 completing the trialGluten free diet for five weeks
Treatment Group: protein shake with rice (25 gms)
Brief Overview of MPRC Double Blind RCT
Control Group: protein shake with gluten (25 gms)Weekly Assessments
SANS BPRS Gastrointestinal Symptom Rating ScaleAGA
Baseline/endpoint Assessments
55
pMatrics Cognitive Battery Proinflammatory Immune MarkersGut permeability: Zonulin, ASCANeuroimaging n = 30
Followup for two months post release
Search for Mechanisms
4/5/2018
29
57
58
4/5/2018
30
It is not just the gut that is leaky!
Serological casein and gluten IgGcorrelate with CSF casein and gluten IgG in
59
g gschizophrenia
60
Psychosomatic Medicine, 2016
4/5/2018
31
Kynurenine higher in persons with schizophrenia in top 10% of IgG values:
Kynurenine/Tryptophan ratio higher in persons
61
Kynurenine/Tryptophan ratio higher in persons with schizophrenia in top 10% of IgG values:
The microbiome may be involved
62
4/5/2018
32
63
Gut Permeability and Mimicry of the Glutamate Ionotropic Receptor NMDA type Subunit Associated with protein 1 (GRINA1) as Potential Mechanisms Related to a Subgroup of People with Schizophrenia with elevated AntigliadinAntibodies (AGA IgG)Running title: GRINA, ASCA and Gliadin Antibodies in Schizophrenia
Daniela Čiháková1, 2 et al Submitted to Biological Psychiatry
•160 persons with schizophrenia and 80 healthy controls
Antibodies to bacteria associated with Leaky Gut
•160 persons with schizophrenia and 80 healthy controls
•association between AGA IgG and ASCA IgG in schizophrenia (p=0.05) suggests permeability of the gut and the blood brain barrier(ASCA = Anti‐Saccharomyces Cerevisiae antibodies, known to be associated with leaky gut)
AGA I G l t d t GRINA1 i ith hi h i GRINA1 i
64
•AGA IgG related to GRINA1 in persons with schizophrenia: GRINA1 is a glutamate receptor similar in structure to gliadin 33‐mer segment
•mimicry through the presence of cross‐reactivity between gliadin and GRINA1 may contribute to inflammation or disruption of glutamate process
4/5/2018
33
65
Magnetic Resonance Spectroscopy in 33 persons with schizophrenia shows that myoinositol in the anterior cingulatecortex is correlated with serum AGA IgG (r=0.47, p < 0.007)
Implications
Identification of a subtype of schizophrenia might lead to better understanding of etiologyg gy
The gliadin-reactive subtype might be affecting as many as 1,000,000 persons
Removal of gluten from the diet is not easy but not i
66
expensive
Gluten withdrawal would be the first new form of treatment for schizophrenia in half a century